Shares of major U.S. health insurers rose sharply after the federal government announced a larger-than-expected increase in Medicare Advantage payment rates for 2027, easing fears that the industry would face another year of margin pressure. The Centers for Medicare & Medicaid Services said it would raise payments to private insurers offering Medicare Advantage plans by an average of 2.48% in 2027. That was far above the 0.09% increase proposed in January and well above what many investors had expected.
The market reaction was immediate. Shares of UnitedHealth rose more than 10%, CVS Health climbed nearly 7%, Humana gained 8%, and Elevance Health added about 3% after the announcement. Investors viewed the new rate as a sign that the government may be taking a less aggressive stance toward the sector after months of concern that reimbursement policies were not keeping up with rising medical costs.
The size of the increase matters because Medicare Advantage has become one of the most important businesses for large health insurers. These plans are privately run alternatives to traditional Medicare and cover millions of older Americans. When payment rates rise, insurers generally gain more room to manage medical costs, design benefits, and protect or rebuild profit margins. Higher rates would translate into more than $13 billion in additional payments in 2027, giving the industry a meaningful financial tailwind.
The decision also marked a reversal in tone from earlier this year. In January, the Trump administration’s initial proposal for 2027 payment rates disappointed Wall Street and sparked backlash from insurers already struggling with financial strain. Companies had lost billions in market value after that earlier proposal because it suggested the government was not fully responding to the sharp rise in healthcare utilization and medical expenses that has squeezed the sector for nearly three years.
But the new rates should improve the industry’s outlook. Mizuho analyst Ann Hynes said the stronger reimbursement increase should help insurers expand margins in 2027, especially when combined with benefit cuts. Leerink analyst Whit Mayo said the move supports the case for margin growth and reduces the perception that CMS had adopted a harsh policy posture toward the group. Oppenheimer analyst Michael Wiederhorn said the industry had remained under pressure, but the more favorable rate announcement may signal that conditions are beginning to improve.
Another important detail is that the headline rate increase does not tell the full story. Insurers will also receive a 2.5% benefit from a change in risk-assessment payments tied to patient health status. According to a Medicare agency, that means the total effective increase is closer to about 5%. That combined uplift helps explain why investors responded so positively: the policy change may do more to support insurer finances than the main payment figure alone suggests.
In broader terms, the announcement shows how sensitive health insurer valuations are to government reimbursement policy. Medicare Advantage is a heavily regulated market, and even small changes in payment formulas can have major effects on company earnings and investor confidence. The January proposal had deepened fears that insurers would continue facing weak margins, but the final 2027 rate suggests Washington may be more willing to ease pressure on the industry than many expected. That does not solve every challenge, since rising medical costs are still a problem, but it does give insurers a clearer path toward stabilizing profitability.
Overall, the move is a meaningful win for the sector. By lifting Medicare Advantage payment rates well above expectations, the government gave major insurers a stronger earnings outlook, reassured investors, and reduced some of the anxiety that had been building since the weaker January proposal.
